AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26371 — intervention group
Group type: COMPARATOR
Intervention: Inhaled Isoprenaline (1,500 microgram)
Number of subjects: 12
Study 29222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (10 mg)
Number of subjects: 24
Study 29222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (30 mg)
Number of subjects: 24
Study 29222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (100 mg)
Number of subjects: 24
Study 29222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (300 mg)
Number of subjects: 24
Study 29222947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26972022 — intervention group
Group type: EXPERIMENTAL
Intervention: fcSEMS
Number of subjects: 54
Study 26972022 — intervention group
Group type: EXPERIMENTAL
Intervention: uSEMS
Number of subjects: 54
Study 26972022 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stents
Number of subjects: 54
Study 25359128 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOW dissemination (facilitator-led participatory approach)
Number of subjects: 30
Study 25359128 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dissemination (one didactic session a year and distribution of educational material)
Number of subjects: 30
Study 25359128 — intervention group
Group type: COMPARATOR
Intervention: Control (no dissemination)
Number of subjects: 30
Study 25359128 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (FLOW, traditional, control)
Number of subjects: 30
Study 23382472 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (HT); n = 70
Number of subjects: 137
Study 23382472 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T‐DM1); n = 67
Number of subjects: 137
Study 21409897 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prunes daily
Number of subjects: 259
Study 21409897 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of prunes
Number of subjects: 259
Study 21409897 — intervention group
Group type: COMPARATOR
Intervention: Control group (plain water)
Number of subjects: 259
Study 21409897 — intervention group
Group type: EXPERIMENTAL
Intervention: Test groups (prunes)
Number of subjects: 259
Study 17905442 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine alone (DLX)
Number of subjects: 962
Study 17905442 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine plus telephone intervention (DLX+TI)
Number of subjects: 962
Study 15938378 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (group I)
Number of subjects: 62
Study 15938378 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral nutrition (group II)
Number of subjects: 62
Study 15938378 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition enriched with glutamine, arginine, and omega-3 fatty acids (group III)
Number of subjects: 62
Study 15938378 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as comparison between groups)
Number of subjects: 62
Study 12826854 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine with naloxone 0.8 mg
Number of subjects: 92
Study 12826854 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (placebo)
Number of subjects: 92
Study 10921562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2.7±0.2 microg x kg(−1) x min(−1))
Number of subjects: 10
Study 10921562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (0.7±0.1 microg x kg(−1) x min(−1))
Number of subjects: 10
Study 10921562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2.7±0.1 microg x kg(−1) x min(−1))
Number of subjects: 10
Study 9120223 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Number of subjects: 16
Study 9120223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8263895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed prescription-refill reminders
Number of subjects: 304
Study 8263895 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-of-use packaging
Number of subjects: 304
Study 8263895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mailed reminders and unit-of-use packaging
Number of subjects: 304
Study 8263895 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 304
Study 2938986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment to control PRL levels during anesthesia
Number of subjects: 20
Study 2938986 — intervention group
Group type: COMPARATOR
Intervention: No bromocriptine treatment
Number of subjects: 20
Study 2938986 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia and follicular aspiration
Number of subjects: 20
Study 2938986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy after embryo transfer
Number of subjects: 20
Study 2938986 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PRL and P levels during oocyte retrieval
Number of subjects: 20
Study 30095660 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.005 mg/kg, intramuscular injection)
Number of subjects: 78
Study 30095660 — intervention group
Group type: COMPARATOR
Intervention: Control (no glycopyrrolate administration)
Number of subjects: 78
Study 27895848 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 3428
Study 27895848 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate
Number of subjects: 3428
Study 27895848 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 3428
Study 27895848 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine-artesunate
Number of subjects: 3428
Study 24115149 — intervention group
Group type: EXPERIMENTAL
Intervention: MS group
Number of subjects: 26
Study 24115149 — intervention group
Group type: COMPARATOR
Intervention: HC group
Number of subjects: 26
Study 22048442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of ASA
Number of subjects: 52
Study 22048442 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of ASA
Number of subjects: 52
Study 20720176 — intervention group
Group type: COMPARATOR
Intervention: EX‐FAST (noncaloric placebo)
Number of subjects: 8
Study 20720176 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐FED (beverage containing 5 kcal, 0.83 g carbohydrate, 0.37 g protein, and 0.03 g fat)
Number of subjects: 8
Study 20720176 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐FED
Number of subjects: 8
Study 20720176 — intervention group
Group type: COMPARATOR
Intervention: EX‐FAST
Number of subjects: 8
Study 18463425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with levocabastine hydrochloride ophthalmic suspension and pemirolast potassium ophthalmic solution
Number of subjects: 32
Study 18463425 — intervention group
Group type: COMPARATOR
Intervention: Single therapy with levocabastine hydrochloride ophthalmic suspension
Number of subjects: 32
Study 16418140 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide IV 0.5 mg 30 minutes before surgery
Number of subjects: 46
Study 16418140 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron IV 0.1 mg 30 minutes before surgery
Number of subjects: 46
Study 16418140 — intervention group
Group type: COMPARATOR
Intervention: Control (saline IV 30 minutes before surgery)
Number of subjects: 46
Study 12908038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine isothionate (4mg/kg/day on alternate days for one week)
Number of subjects: 79
Study 12908038 — intervention group
Group type: COMPARATOR
Intervention: N-methylglucamine (20mgSbV/kg/day for 20 days)
Number of subjects: 79
Study 12908038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine isothionate
Number of subjects: 79
Study 12908038 — intervention group
Group type: COMPARATOR
Intervention: N-methylglucamine
Number of subjects: 79
Study 10390744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg t.i.d. for one year
Number of subjects: 156
Study 10390744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 10390744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 156
Study 8695026 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 50
Study 8695026 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 1716546 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg hydrocortisone per day
Number of subjects: 62
Study 1716546 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg hydrocortisone per day
Number of subjects: 62
Study 1716546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 6370437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (6 to 2 mg over 4 days)
Number of subjects: 50
Study 6370437 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (150 to 50 mg over 4 days)
Number of subjects: 50
Study 30653086 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg elemental selenium daily)
Number of subjects: 90
Study 30653086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30158360 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a person in need of nursing care at home
Number of subjects: 38958
Study 30158360 — intervention group
Group type: COMPARATOR
Intervention: No person in need of nursing care at home
Number of subjects: 38958
Study 26685791 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol 6 times a day
Number of subjects: 86
Study 26685791 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate 6 times a day
Number of subjects: 86
Study 24639290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked spongostan
Number of subjects: 121
Study 24639290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spongostan)
Number of subjects: 121
Study 22677076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin (1000 mg twice daily) and pioglitazone (45 mg daily) for 3 months
Number of subjects: 25
Study 22677076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20673557 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine and behavior therapy
Number of subjects: 56
Study 20673557 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine alone
Number of subjects: 56
Study 17392557 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nut diet
Number of subjects: 42
Study 17392557 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 42
Study 17392557 — intervention group
Group type: COMPARATOR
Intervention: Control diet (DASH)
Number of subjects: 42
Study 16344837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS XR) 20-60 mg/day
Number of subjects: 223
Study 11897264 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized pheromone
Number of subjects: 36
Study 11897264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11122690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 0
Study 11122690 — intervention group
Group type: COMPARATOR
Intervention: Baseline LDL-C levels as low as 125 mg/dL
Number of subjects: 0
Study 7533484 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydromorphone via PCA
Number of subjects: 16
Study 7533484 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone via PCA
Number of subjects: 16
Study 1732238 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200
Study 1732238 — intervention group
Group type: COMPARATOR
Intervention: Total meniscectomy
Number of subjects: 200
Study 1732238 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy and Total meniscectomy
Number of subjects: 200
Study 6372846 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release theophylline
Number of subjects: 18
Study 6372846 — intervention group
Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 18
Study 6372846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 29447357 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized releases of Wolbachia-infected Aedes aegypti mosquitoes
Number of subjects: 0
Study 29447357 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29533819 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz 2 mA peak-to-peak tACS
Number of subjects: 22
Study 29533819 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 29533819 — intervention group
Group type: COMPARATOR
Intervention: 2 mA tDCS
Number of subjects: 22
Study 29533819 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS, sham, and tDCS
Number of subjects: 22
Study 26188918 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior calyceal access (Group 1)
Number of subjects: 100
Study 26188918 — intervention group
Group type: COMPARATOR
Intervention: Inferior calyceal access (Group 2)
Number of subjects: 100
Study 24091353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based snack (high-sugar and high-glycemic index)
Number of subjects: 79
Study 24091353 — intervention group
Group type: COMPARATOR
Intervention: Raisin-based snack
Number of subjects: 79
Study 24091353 — intervention group
Group type: COMPARATOR
Intervention: Peanut-butter-based snack
Number of subjects: 79
Study 22168750 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone derivative plus onion extract gel (Cybele(®) scagel)
Number of subjects: 60
Study 22168750 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 20399336 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor depression (2-4 symptoms)
Number of subjects: 1129
Study 20399336 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression (5-6 symptoms)
Number of subjects: 1129
Study 20399336 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression (7-9 symptoms)
Number of subjects: 1129
Study 20399336 — intervention group
Group type: COMPARATOR
Intervention: Comparison of minor and major depression
Number of subjects: 1129
Study 18633050 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% at 8 mL/h with 3-mL bolus and 15-min lockout (15-min lockout group)
Number of subjects: 37
Study 18633050 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% at 4 mL/h with 8-mL bolus and 30-min lockout (30-min lockout group)
Number of subjects: 37
Study 16170975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth wipe (Oral‐B Brush‐Ups)
Number of subjects: 25
Study 16170975 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 25
Study 12238997 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program focusing on education and supervision of coaches and players
Number of subjects: 194
Study 12238997 — intervention group
Group type: COMPARATOR
Intervention: Usual training and playing without intervention
Number of subjects: 194
Study 12238997 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program
Number of subjects: 194
Study 9146440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity dietary intervention (self-help booklet and brief motivational message)
Number of subjects: 2111
Study 7959278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (used for at least 1 year, median duration 4.5 years)
Number of subjects: 73
Study 7959278 — intervention group
Group type: COMPARATOR
Intervention: No Tamoxifen
Number of subjects: 73
Study 7959278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 73
Study 3125307 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone analogue (RX77368)
Number of subjects: 29
Study 29383372 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling journal group
Number of subjects: 0
Study 29383372 — intervention group
Group type: COMPARATOR
Intervention: Gratitude journal group
Number of subjects: 0
Study 27028750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DP fast-melt formulation of levetiracetam
Number of subjects: 33
Study 27028750 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate-release tablet of levetiracetam (Keppra(®))
Number of subjects: 33
Study 27028750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DP fast-melt formulation of levetiracetam under fed conditions
Number of subjects: 33
Study 24030782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 64
Study 24030782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal 0.9% saline infusion)
Number of subjects: 64
Study 22426346 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT + Ranibizumab
Number of subjects: 61
Study 22426346 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Number of subjects: 61
Study 22426346 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 61
Study 20132969 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 16
Study 20132969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19039458 — intervention group
Group type: EXPERIMENTAL
Intervention: Zyoptix LASIK
Number of subjects: 37
Study 19039458 — intervention group
Group type: COMPARATOR
Intervention: Planoscan LASIK
Number of subjects: 37
Study 16871592 — intervention group
Group type: EXPERIMENTAL
Intervention: MINO (Aerocrine)
Number of subjects: 55
Study 16871592 — intervention group
Group type: COMPARATOR
Intervention: NIOX
Number of subjects: 55
Study 14639068 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapies
Number of subjects: 0
Study 14639068 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis
Number of subjects: 0
Study 14639068 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dialysis
Number of subjects: 0
Study 14639068 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible membranes
Number of subjects: 0
Study 14639068 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow extended daily dialysis
Number of subjects: 0
Study 11200149 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/5-FU/leucovorin combinations
Number of subjects: 0
Study 11200149 — intervention group
Group type: COMPARATOR
Intervention: Standard 5-FU/leucovorin regimens
Number of subjects: 0
Study 8831922 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate given orally
Number of subjects: 62
Study 8831922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1287614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 375 mg twice daily
Number of subjects: 1321
Study 1287614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 500 mg twice daily
Number of subjects: 1321
Study 1287614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 750 mg twice daily
Number of subjects: 1321
Study 1287614 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily
Number of subjects: 1321
Study 1287614 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg three times daily
Number of subjects: 1321
Study 3891682 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone 150 mg
Number of subjects: 117
Study 3891682 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone 75 mg
Number of subjects: 117
Study 3891682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 31560093 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based adherence clubs
Number of subjects: 604
Study 31560093 — intervention group
Group type: COMPARATOR
Intervention: Community-based adherence clubs
Number of subjects: 604
Study 30044398 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational product containing extracts of white mulberry, white bean, and green coffee (with added fibre)
Number of subjects: 182
Study 30044398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 25763849 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-strand hamstring tendon (HT) allograft
Number of subjects: 129
Study 25763849 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) allograft
Number of subjects: 129
Study 24433461 — intervention group
Group type: EXPERIMENTAL
Intervention: Village doctor-assisted case management (VD model)
Number of subjects: 400
Study 24433461 — intervention group
Group type: COMPARATOR
Intervention: Case as usual (CAU model)
Number of subjects: 400
Study 23226534 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 126
Study 23226534 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 126
Study 23226534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 20220605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua-Sha therapy (scraping therapy)
Number of subjects: 54
Study 20220605 — intervention group
Group type: COMPARATOR
Intervention: Traditional breast care (massage and heating)
Number of subjects: 54
Study 18560342 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens therapy
Number of subjects: 50
Study 18560342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16326677 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.03 microg.kg(‐1).min(‐1)
Number of subjects: 58
Study 16326677 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.06 microg.kg(‐1).min(‐1)
Number of subjects: 58
Study 16326677 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.12 microg.kg(‐1).min(‐1)
Number of subjects: 58
Study 16326677 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg.kg(‐1).min(‐1)
Number of subjects: 58
Study 12183768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectatic infrarenal aorta (2.5‐2.9 cm diameter)
Number of subjects: 223
Study 12183768 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance protocol (repeat ultrasound)
Number of subjects: 223
Study 9890490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pentifylline (800 mg) and nicotinic acid (200 mg) daily
Number of subjects: 30